Theravance and Astellas report results from pre-clinical studies with investigational antibiotic Telavancin.

(From Chemical Business NewsBase - Press Release)

Theravance Inc announced that results of pre-clinical studies with telavancin were presented at the 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington, DC. Telavancin is a novel lipoglycopeptide injectable antibiotic discovered by Theravance that is currently in development for serious Gram-positive infections including those caused by drug-resistant Staphylococcus aureus strains. Telavancin is currently being evaluated in Phase III studies for its safety and efficacy in the treatment of complicated skin and skin structure infections and hospital-acquired …